Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Bullboard Posts
Comment by princeofcuton Apr 23, 2015 11:40am
110 Views
Post# 23657141

RE:RE:RE:Don on BNN

RE:RE:RE:Don on BNNROTFLMAO.. so tundup you don't think he misspoke, well i gotta propose you as "rube of the year" is it that you know nothing about ODD trials, or the $600M cardiac trial or are you really just a pumpertrashole...it is inconceivable to believe that even DM would rationally equate ODD trials to the $600M trial...ODD are very narrow indications the $600M 6year trial he was referencing was the likely next 208 trial (cardiac centric) they were faced with until BOM came along..two entirely separate worlds  man what a board of fools..DM simply misspoke and he has a history of that...PS if i am proven wrong i will issue an apolgy to DM on this MB
..lastly you should read up on ODD clinical path before you post your misinformation, ODD follows typical clinical paths you don't start at PIII for ODD
Bullboard Posts